Chapter 47: Common Reproductive System Issues

The contraception and family planning section examines diverse contraceptive options categorized by mechanism and effectiveness, including long-acting reversible methods such as intrauterine devices and subdermal implants that exceed 99% efficacy, hormonal approaches ranging from combined oral formulations to transdermal delivery systems that bypass hepatic metabolism, and barrier techniques essential for sexually transmitted infection prevention. The framework for contraceptive selection incorporates personal preferences, individual health status, and standardized medical eligibility criteria that stratify safety profiles across four risk categories. The infertility section defines the condition as failure to conceive following 12 months of regular unprotected intercourse and identifies multifactorial etiologies including spermatogenesis defects, ovulatory dysfunction, endometriosis, and tubal pathology. Diagnostic evaluation prioritizes semen analysis for male assessment and ovulation tracking combined with tubal patency studies for female evaluation, while management progresses from lifestyle optimization through pharmacological ovulation induction to advanced assisted reproductive technologies. Premenstrual syndrome and its severe variant, premenstrual dysphoric disorder, are characterized by cyclical luteal-phase symptoms linked to hormonal modulation of serotonergic function, with diagnosis confirmed through symptom tracking over multiple cycles and management achieved through selective serotonin reuptake inhibitors and targeted micronutrient supplementation. Menopause is presented as the permanent physiological transition following 12 consecutive months of amenorrhea, resulting from progressive ovarian follicle depletion and consequent estrogen decline with accompanying follicle-stimulating hormone elevation. Clinical manifestations include vasomotor phenomena, genitourinary atrophy, and accelerated bone loss, managed through lifestyle modifications, pharmacological intervention with serotonin-norepinephrine reuptake inhibitors, localized vaginal hormone therapy, and bone-protective agents including bisphosphonate medications for osteoporosis prevention.